Contents

Preface *XVII*
List of Contributors *XXI*

1 From Milligrams to Tons: The Importance of Synthesis and Process Research in the Development of New Drugs *1*
Martin Karpf
1.1 Introduction *1*
1.2 The Synthetic Development of the Monoamine Oxidase-B Inhibitor Lazabemide™ *6*
1.3 The Synthetic Development of the Lipase Inhibitor Tetrahydrolipstatin (Xenical™) *6*
1.4 The Synthetic Development of the HIV Protease Inhibitor Saquinavir (Invirase™) *13*
1.5 The Synthetic Development of the Influenza Neuraminidase Inhibitor Oseltamivir Phosphate (Tamiflu™) *16*
1.5.1 Introduction *16*
1.5.2 The Development of the Current Technical Synthesis of Oseltamivir Phosphate *18*
1.5.3 The Search for Alternative Routes to Oseltamivir Phosphate *23*
1.5.3.1 The Development of Azide-Free Transformations of the Key Epoxide Intermediate to Oseltamivir Phosphate *23*
1.5.3.2 The Development of Alternative Syntheses for Oseltamivir Phosphate *27*
References *36*

2 Design of Dynamic Salt Catalysts Based on Acid–Base Combination Chemistry *39*
Kazuaki Ishihara
2.1 Introduction *39*
2.2 Dehydrative Condensation Catalysts *41*

Pharmaceutical Process Chemistry. Edited by Takayuki Shioiri, Kunisuke Izawa, and Toshiro Konoike

ISBN: 978-3-527-32650-1

2.2.1 Esterification Catalysts *41*
2.2.2 Dehydrative Cyclocondensation Catalysts *43*
2.3 Asymmetric Mannich-Type Catalysts *50*
References *56*

3 Asymmetric Oxidation with Hydrogen Peroxide, an Effective and Versatile Oxidant *59*
Tsutomu Katsuki
3.1 Introduction *59*
3.2 Asymmetric Epoxidation *60*
3.2.1 Asymmetric Epoxidation with Synthetic Enzymes or Organocatalysts *60*
3.2.2 Metal-Catalyzed Asymmetric Epoxidation of Unfunctionalized Olefins *62*
3.2.3 Metal-Catalyzed Asymmetric Epoxidation of Allylic Alcohols *67*
3.3 Asymmetric Oxidation of Sulfides *67*
3.3.1 Metal–Salen-Catalyzed Oxidation *68*
3.3.2 Metal–Schiff Base-Catalyzed Oxidation *68*
3.3.3 Metal–ONNO–Tetradentate Ligand-Catalyzed Oxidation (Including *cis-β* Metal–Salen-Catalyzed Oxidation) *69*
3.3.4 Miscellaneous *72*
3.4 Conclusion *73*
References *74*

4 Development of Palladium Catalysts for Chemoselective Hydrogenation *77*
Hironao Sajiki and Yasunari Monguchi
4.1 Catalyst Poisons and Chemoselective Heterogeneous Catalysts *77*
4.1.1 Background *77*
4.1.2 Chemoselective Inhibition of the Hydrogenolysis for *O*-Benzyl Protective Groups by the Addition of a Nitrogen-Containing Base *77*
4.1.3 Pd/C(en) Complex as a Heterogeneous Chemoselective Hydrogenation Catalyst *81*
4.1.4 Pd/C (Ph_2S) Complex as a Heterogeneous Chemoselective Hydrogenation Catalyst *85*
4.2 Catalyst Supports and Chemoselective Heterogeneous Catalysts *90*
4.2.1 Pd/Fib as a Silk-Fibroin-Supported Chemoselective Hydrogenation Catalyst *90*
4.2.2 Pd-PEI as a Partial Hydrogenation Catalyst of Alkynes to Alkenes *93*
4.3 Summary *96*
Acknowledgment *97*
References *97*

5 Silicon-Based Carbon–Carbon Bond Formation by Transition Metal Catalysis *101*
Yoshiaki Nakao and Tamejiro Hiyama
5.1 Introduction *101*
5.2 Cross-Coupling Reactions *102*
5.2.1 Brief Assessment of Early Stage Protocols *102*
5.2.2 Cross-Coupling Reactions Using Tetraorganosilanes through Intramolecular Activation *103*
5.2.3 Cross-Coupling Reactions Using Organosilanolates *106*
5.2.4 Other Tetraorganosilicon Compounds for Cross-Coupling Chemistry *108*
5.2.5 New Types of Electrophiles for Silicon-Based Cross-Coupling *111*
5.3 Carbonyl Addition Reaction *114*
5.3.1 Rhodium-Catalyzed Reactions *114*
5.3.2 Nickel-Catalyzed Reactions *115*
5.3.3 Palladium-Catalyzed Reactions *117*
5.3.4 Copper-Catalyzed Reactions *120*
5.3.5 Silver-Catalyzed Reactions *121*
5.4 Recent Developments in Catalytic Preparation of Organosilanes *121*
References *123*

6 Direct Reductive Amination with Amine Boranes *127*
Karl Matos and Elizabeth R. Burkhardt
6.1 Introduction *127*
6.2 Types of Amine Boranes *128*
6.2.1 Alkylamine Boranes *128*
6.2.2 Aromatic Amine Boranes *129*
6.2.2.1 Pyridine borane *130*
6.2.2.2 2-Picoline borane *131*
6.2.2.3 5-Ethyl-2-methylpyridine borane *131*
6.3 Comparison to Sodium Triacetoxyborohydride (STAB) *134*
6.4 Primary Amine Synthesis *135*
6.5 Stereoselective Reductive Amination *137*
6.6 Reaction Solvents *138*
6.7 Reaction Workup *138*
6.8 Conclusion *141*
References *141*

7 Industrial Synthesis of Perfluorinated Building Blocks by Liquid-Phase Direct Fluorination *145*
Takashi Okazoe
7.1 Introduction *145*
7.2 History of Direct Fluorination *146*
7.3 Synthetic Methods Using Perfluorinated Acyl Fluorides for Industrially Important Perfluorinated Monomers *149*

7.3.1 Direct Application of Liquid-Phase Fluorination *149*
7.3.2 The PERFECT Method *150*
7.4 Synthesis of Perfluorinated Building Blocks by the PERFECT Method *152*
7.4.1 Perfluorinated Acyl Fluorides *152*
7.4.2 Synthesis of Perfluorinated Ketones by the PERFECT Method *154*
7.5 Conclusion *156*
References *157*

8 Cross-Linked Enzyme Aggregates as Industrial Biocatalysts *159*
Roger A. Sheldon
8.1 Introduction *159*
8.2 Cross-Linked Enzyme Aggregates *160*
8.2.1 Cross-Linking Agents *160*
8.2.2 Protocols for CLEA Preparation *161*
8.2.3 Advantages of CLEAs *163*
8.2.4 Multi-CLEAs and Combi-CLEAs *164*
8.3 CLEAs from Hydrolases *164*
8.3.1 Lipase and Esterase CLEAs *165*
8.3.2 Protease CLEAs *168*
8.3.3 Amidase CLEAs *170*
8.3.4 Nitrilases *171*
8.3.5 Glycosidases *172*
8.4 Oxidoreductases *172*
8.4.1 Oxidases *172*
8.4.2 Peroxidases *173*
8.5 Lyases *174*
8.5.1 Nitrile Hydratases *174*
8.5.2 C–C Bond Forming Lyases *174*
8.6 Combi-CLEAs and Cascade Processes *175*
8.7 Reactor Design *176*
8.7.1 Membrane Slurry Reactor *177*
8.7.2 CLEAs in Microchannel Reactors *177*
8.8 Conclusions and Prospects *178*
References *178*

9 Application of Whole-Cell Biocatalysts in the Manufacture of Fine Chemicals *183*
Michael Schwarm
9.1 Introduction: Early Applications of Biocatalysis for Amino Acid Manufacture at Evonik Degussa *183*
9.2 Hydantoinase Biocatalysts *187*
9.3 Amino Acid Dehydrogenase Biocatalysts *191*
9.4 Alcohol Dehydrogenase Biocatalysts *195*

9.5 Summary *203*
Acknowledgments *204*
References *204*

10 Process Development of Amrubicin Hydrochloride, an Anthracycline Anticancer Drug *207*
Kazuhiko Takahashi and Mitsuharu Hanada
10.1 Introduction *207*
10.2 Original Synthetic Route for Amrubicin *208*
10.3 Amrubicin Bulk Production Synthetic Method *210*
10.3.1 Safe Synthetic Method of 9-Aminoketone *211*
10.3.2 Stereoselective Introduction of 7-Hydroxy Group *213*
10.3.3 Polymorphism Study of Amrubicin Hydrochloride *215*
10.3.4 Stability of Amrubicin Hydrochloride with Reference to Moisture *216*
10.3.4.1 Amrubicin Hydrochloride Moisture Adsorption *217*
10.3.4.2 Stability in Various Water Contents *217*
10.3.4.3 Establishment of Drying Method *217*
10.4 Conclusion *219*
References *219*

11 Process Development of HIV Integrase Inhibitor S-1360 *221*
Toshiro Konoike and Sumio Shimizu
11.1 Introduction *221*
11.2 Discovery of Integrase Inhibitor S-1360 *221*
11.2.1 Discovery Route of S-1360 *222*
11.3 Synthesis of Two Starting Materials for S-1360 *225*
11.3.1 Two One-Step Syntheses of Benzylfuryl Methyl Ketone **2** *225*
11.3.1.1 Friedel–Crafts Alkylation by Anhydrous $ZnCl_2$ in Dichloromethane *226*
11.3.1.2 Friedel–Crafts Alkylation Using Aqueous $ZnCl_2$ *226*
11.3.2 Two Synthetic Methods to Triazole Ester **3** *228*
11.3.2.1 Ring Construction Method *228*
11.3.2.2 Ring Modification Method *228*
11.4 Process Chemistry of S-1360 and Scale-Up of THP Route *229*
11.4.1 Protection of Triazole **3** by the Tetrahydropyranyl (THP) Group and Claisen Condensation *229*
11.4.2 Deprotection of the THP Group and Purification of API Deprotection of the THP Group *230*
11.4.2.1 Purification of API *231*
11.4.2.2 Quality Assurance and Productivity *232*
11.5 Process Development of S-1360 and Commercial Route by Methoxyisopropyl (MIP) Protection *233*
11.5.1 MIP Route *234*
11.5.2 Further Improvement of Productivity *235*

11.6 Summary and Outlook *235*
Acknowledgments *237*
References *237*

12 An Efficient Synthesis of the Protein Kinase Cβ Inhibitor JTT-010 *239*
Takashi Inaba
12.1 Introduction *239*
12.2 Synthetic Strategies *240*
12.3 Key Intermediate Synthesis *240*
12.3.1 Optical Resolution *240*
12.3.2 Enzymatic Chiral Induction *242*
12.3.3 C–H Bond Activation by a Chiral Catalyst *243*
12.3.4 Formal [3 + 2] Cycloaddition Using Chiral Cyclopropane *244*
12.4 Replacement of the Hydroxyl Group of **1** with an Amino Group *250*
12.5 Construction of JTT-010 *251*
12.5.1 Stepwise Maleimide Construction *251*
12.5.2 Convergent Coupling Reaction to JTT-010 *251*
12.6 Conclusion *253*
References *254*

13 Process Development of Oral Carbapenem Tebipenem Pivoxil, TBPM-PI *257*
Takao Abe and Masataka Kitamura
13.1 Introduction *257*
13.2 Discovery of TBPM-PI *257*
13.3 Synthetic Process of Side Chain on the C2-Position of TBPM, TAT *260*
13.3.1 Original Synthetic Process of TAT Starting from Benzhydrylamine *260*
13.3.2 Practical Synthetic Process of TAT from Benzylamine *261*
13.3.3 Industrial Synthetic Process of TAT: Back to Classic Bunte's Salt *263*
13.4 Synthetic Process of TBPM-PI from 4-Nitrobenzyl (1*R*,5*R*,6*S*)-2-diphenylphosphoryloxy-6-[(*R*)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate, MAP *265*
13.4.1 Synthesis of PNB Ester of TBPM, L-188 *265*
13.4.2 Synthesis of TBPM-4H_2O *266*
13.4.3 Prodrug Esterification: Synthesis of TBPM Hexetil, LJC11,143 *267*
13.4.4 Synthesis of TBPM-PI *269*
13.5 Summary and Outlook *270*
Acknowledgments *271*
References *271*

14 Some Progress in Organic Synthesis of Pharmaceuticals in China *273*
Delong Liu and Wanbin Zhang
14.1 Introduction *273*
14.2 Industrial Synthesis of Chinese Herbal Medicines *274*
14.2.1 Industrial Synthesis of Berberine *274*
14.2.2 Industrial Synthesis of D,L-Tetrahydropalmatine (THP) *277*
14.3 New Agents Derived from Chinese Herbal Medicines *281*
14.3.1 Bifendate and Bicyclol *281*
14.3.1.1 Bifendate *281*
14.3.1.2 Bicyclol *284*
14.3.2 Qinghaosu *285*
14.3.2.1 Synthesis *285*
14.3.2.2 Fixed-Dose Riamet/Coartem *287*
14.4 Process Chemistry for L-Ascorbic Acid and Biotin *291*
14.4.1 Two Steps Fermentation Method for the Preparation of L-Ascorbic Acid (Vitamin C) *291*
14.4.2 Total Synthesis of Biotin (Vitamin B7) *294*
14.5 Conclusion and Perspectives *298*
Abbreviations *299*
References *299*

15 The Use of Continuous Processing to Make AZD 4407 Intermediates *303*
Andrew S. Wells
15.1 Green Chemistry and the Drive for Sustainability *303*
15.2 Advantages of Chemistry in Continuous-Flow Reactors *304*
15.3 Introduction to AZD 4407 *305*
15.4 Comparison of the Synthetic Routes Used to Prepare AZD 4407 *305*
15.5 Conversion of Batch to a Flow Process *308*
15.5.1 Preparation of Synthons Used in the Microreactor Study *308*
15.5.1.1 Disulfide Synthesis *308*
15.5.1.2 (*S*)-2-Methyl Tetrahydropyran-4-one *309*
15.5.1.3 Thiophene Synthon *310*
15.5.2 *n*-Hexyl Lithium Versus *n*-Butyl Lithium *310*
15.5.3 Batch Reactions: Lithiation Reaction and Disulfide Linking *311*
15.5.4 Microreactor Description *311*
15.5.5 Lithiation Reaction in Flow Mode *312*
15.5.6 Coupling Reaction with Disulfide in Flow Mode *313*
15.5.7 Linking the Lithiation and Reaction with Disulfide in Flow Mode *313*
15.6 Conclusions *316*
Acknowledgments *317*
References *317*

16 Sustainable Processes Based on Enzymes Enabling 100% Yield and 100% ee Concepts *321*
Oliver May
16.1 Introduction *321*
16.2 Asymmetric Synthesis *322*
16.2.1 C–C Bond Formations *322*
16.2.2 Production of Chiral Alcohols by Enzymatic Reduction of Ketones *325*
16.2.3 Reduction of Activated C=C Bonds *326*
16.2.4 Reductive Amination of α-Keto-Acids for the Production of α-Amino Acids *328*
16.2.5 Transamination Reactions *330*
16.3 Enzymatic Desymmetrization *332*
16.4 Enzymatic Deracemization *335*
16.5 Dynamic Kinetic Resolution *337*
16.6 Summary and Outlook *338*
References *339*

17 Development of a Novel Synthetic Method for RNA Oligomers *345*
Tadaaki Ohgi and Junichi Yano
17.1 Introduction *345*
17.2 Synthesis of CEM Amidites *349*
17.3 Synthesis of RNA Oligomers from CEM Amidites *350*
Acknowledgments *360*
References *360*

18 Process Research with Explosive Reactions *363*
Hiromu Kawakubo
18.1 Introduction *363*
18.2 Safety Evaluation of an Explosive Chemical Process *363*
18.3 Standard Procedures for Risk Assessment *365*
18.3.1 CHETAH (Chemical Thermodynamic and Energy Release Evaluation Program) Calculation *365*
18.3.2 DSC (Differential Scanning Calorimetry) *365*
18.3.3 DTA (Differential Thermal Analysis) and TG (Thermogravimetry) *367*
18.3.4 Impact Sensitivity Test *368*
18.3.5 Friction Sensitivity Test *368*
18.3.6 Pressure Vessel Test *369*
18.3.7 Steel Pipe Test *371*
18.4 Safety Evaluation of Nitroacetic Acid Ethyl Ester *371*
18.4.1 Various Safety Evaluations of Nitroacetic Acid Ethyl Ester *373*
18.4.2 Synthesis of Nitroacetic Acid Ethyl Ester and Its Risk Assessment *374*

18.5 Development of an Efficient Method for the Synthesis of Nitrobenzene Derivatives *376*
References *380*

19 Scientific Strategy for Optical Resolution by Salt Crystallization: New Methodologies for Controlling Crystal Shape, Crystallization, and Chirality of Diastereomeric Salt *381*
Rumiko Sakurai and Kenichi Sakai
19.1 Introduction *381*
19.2 Control of Crystal Shape: Crystal Habit Modification *382*
19.2.1 Significance of Crystal Shape in Industrial-Scale Production *382*
19.2.2 Effective Additive for Controlling Crystal Shape *384*
19.2.3 Mechanism of Crystal Habit Modification *385*
19.3 Control of Crystallization: Concept of Space Filler *387*
19.3.1 Evaluation of Molecular Size *387*
19.3.2 Concept of Space Filler *388*
19.3.3 Resolution of MMT *388*
19.3.4 Crystal Structures of the Salts *390*
19.4 Control of Chirality: Dielectrically Controlled Optical Resolution (DCR) *391*
19.4.1 DCR *391*
19.4.1.1 DCR in Resolution of (*RS*)-ACL with (*S*)-TPA *391*
19.4.1.2 DCR in Resolution of (*RS*)-PTE with (*S*)-MA *394*
19.5 Conclusion and Prospect *397*
References *397*

20 Development of New Drug and Crystal Polymorphs *401*
Mitsuhisa Yamano
20.1 Introduction *401*
20.2 Scope of Crystal Polymorphs *402*
20.3 Late-Appearing Polymorphs *402*
20.4 Late-Appearing Polymorphs as a Process Research Issue *403*
20.5 Drug Substance Form Selection *404*
20.6 Polymorph Screening *405*
20.7 Thermodynamically Stable Polymorphs *406*
20.7.1 One-Component System *406*
20.7.2 Multicomponent System *406*
20.8 Polymorph Control *409*
20.8.1 Nucleation and Seeding *411*
20.8.2 Ostwald's Stage Rule *411*
20.8.3 Unintentional Seeding *416*
20.9 Primary Nucleation *416*
20.10 Summary *417*
Acknowledgments *418*
References *418*

21 Development of LIPOzymes Based on Biomembrane Process Chemistry *421*
Hiroshi Umakoshi, Toshinori Shimanouchi, and Ryoichi Kuboi
21.1 Introduction *421*
21.2 From "Process Chemistry" to "Biomembrane Process Chemistry" *422*
21.3 Recognition (Separation) Function of Liposomes *425*
21.4 LIPOzyme: Liposome with Enzyme-Like Activity? *428*
21.4.1 Break-Down Type LIPOzyme *428*
21.4.2 Build-Up Type LIPOzyme *431*
21.5 Biomembrane Interference *433*
21.6 Summary *438*
Acknowledgments *439*
References *439*

22 Matching Chemistry with Chemical Engineering for Optimum Design and Performance of Pharmaceutical Processing *443*
Amit V. Mahulkar, Parag R. Gogate, and Aniruddha B. Pandit
22.1 Concept of Molecule to Money *443*
22.2 Steps Involved in Bringing Molecule to Market *444*
22.2.1 Synthesis in Lab *444*
22.2.2 Kilo Lab *445*
22.2.3 Pilot Plant *446*
22.2.4 Full-Scale Plant *447*
22.3 Interrelation in Each Step and Concept of Unit Operations *448*
22.4 Unit Operations *449*
22.4.1 Mixing *449*
22.4.1.1 Utility of Mixing *449*
22.4.1.2 Types of Equipments *449*
22.4.1.3 Selection Criteria *451*
22.4.2 Crystallization *452*
22.4.2.1 Utility of Crystallization *452*
22.4.2.2 Types of Equipments *452*
22.4.2.3 Selection Criteria *453*
22.4.3 Filtration and Centrifugation *454*
22.4.3.1 Utility of Filtration *454*
22.4.3.2 Types of Equipments *455*
22.4.3.3 Selection Criteria for Filtration *457*
22.4.4 Centrifugation *458*
22.4.4.1 Utility of Centrifugation *458*
22.4.4.2 Types of Equipments *458*
22.4.4.3 Selection Criteria *460*
22.4.5 Drying *460*
22.4.5.1 Utility of Drying *460*
22.4.5.2 Types of Equipments *461*

22.4.5.3 Selection Criteria *463*
22.5 Scale-up Problems *464*
22.6 Optimization and Intensification of Unit Operations *464*
22.6.1 Step I: Establishing Material and Energy Balance across All the Equipments *465*
22.6.2 Step II: Preliminary Evaluation of All the Major Equipments *465*
22.6.3 Step III: Analysis of All the Operations and Equipments at Relatively Intricate Levels *465*
22.6.4 Step IV: Mathematical Modeling of Individual Equipment and Subsequently the Entire Plant *465*
22.7 Summary *466*
References *466*

23 The Integration of Safety, Health, and Environmental Considerations into Process Development *469*
Wesley White, Vyv Coombe, and Jonathan Moseley
23.1 Introduction *469*
23.1.1 The SHE Triggers Model *469*
23.1.2 Introduction to AZD4619 *473*
23.2 Process Safety *474*
23.2.1 Assessment of Chemical Reaction Hazards *475*
23.2.2 Assessment of Operational Hazards *475*
23.2.3 Basis of Safety *475*
23.2.4 Process Safety Triggers *476*
23.2.4.1 Early Delivery *476*
23.2.4.2 Later Process Safety Triggers *476*
23.2.4.3 Technology Transfer *477*
23.2.5 Application of Process Safety to AZD4619 *477*
23.2.5.1 General Hazards of Aqueous Diazotization and the Basis of Safety *477*
23.2.5.2 Additions of Acetone, Water, Hydrochloric Acid, and Acrylic Acid *478*
23.2.5.3 Addition of Sodium Nitrite *478*
23.3 Health *479*
23.3.1 Introduction *479*
23.3.2 Health Triggers *479*
23.3.2.1 Early Delivery *479*
23.3.2.2 Synthetic Route Evaluation *480*
23.3.2.3 Process Design *480*
23.3.2.4 Process Optimization and Understanding *481*
23.3.2.5 Technology Transfer *481*
23.3.3 Application of Health Triggers to AZD4619 *482*
23.4 Environment *482*
23.4.1 Introduction *482*
23.4.2 Environment Triggers *482*

23.4.2.1 Early Delivery and Synthetic Route Evaluation *482*
23.4.2.2 Process Design *484*
23.4.2.3 Process Optimization and Understanding *484*
23.4.2.4 Technology Transfer *485*
23.4.3 Application of Environmental Triggers to AZD4619 *485*
23.5 The Use of Risk Assessment *486*
23.6 Conclusion *487*
Acknowledgments *488*
References *488*

Index *489*